Rapid Pathogen Screening
RPS Diagnostics (RPS) is an emerging developer, manufacturer, and marketer of cost-effective point-of-care (POC) tests for systemic infectious disease and antibiotic stewardship. The company's innovative and patented FebriDx test is a rapid, disposable, in-office test that uses a finger stick blood sample to help identify a clinically significant immune response and differentiate bacterial from viral causes for fever in acute respiratory infection. With a 97% negative predictive value, FebriDx delivers results in 15 minutes and can be used to help triage infectious patients during the initial office visit, providing clinicians with actionable information that can be used to limit unnecessary antibiotics.
About Rapid Pathogen Screening
Founded
2004Estimated Revenue
$1M-$10MEmployees
11-50Funding / Mkt. Cap
$35MCategory
Industry
BiotechnologyLocation
City
SarasotaState
FloridaCountry
United StatesRapid Pathogen Screening
Find your buyer within Rapid Pathogen Screening